Nothing Special   »   [go: up one dir, main page]

ATE306921T1 - Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose - Google Patents

Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose

Info

Publication number
ATE306921T1
ATE306921T1 AT01124669T AT01124669T ATE306921T1 AT E306921 T1 ATE306921 T1 AT E306921T1 AT 01124669 T AT01124669 T AT 01124669T AT 01124669 T AT01124669 T AT 01124669T AT E306921 T1 ATE306921 T1 AT E306921T1
Authority
AT
Austria
Prior art keywords
arteriosclerosis
treatment
olmersartan
medication
production
Prior art date
Application number
AT01124669T
Other languages
English (en)
Inventor
Yoshio Tsujita
Toshihiko Fujiwara
Toshio Sada
Naoyuki Maeda
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE306921T1 publication Critical patent/ATE306921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT01124669T 1996-07-15 1997-07-11 Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose ATE306921T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15

Publications (1)

Publication Number Publication Date
ATE306921T1 true ATE306921T1 (de) 2005-11-15

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01124669T ATE306921T1 (de) 1996-07-15 1997-07-11 Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose
AT97930762T ATE283704T1 (de) 1996-07-15 1997-07-11 Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97930762T ATE283704T1 (de) 1996-07-15 1997-07-11 Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom

Country Status (19)

Country Link
US (1) US6610682B2 (de)
EP (2) EP1175902B1 (de)
KR (1) KR100540618B1 (de)
CN (2) CN1221259C (de)
AT (2) ATE306921T1 (de)
AU (1) AU714618B2 (de)
CA (1) CA2261040C (de)
CZ (2) CZ299162B6 (de)
DE (2) DE69734405T2 (de)
DK (2) DK1175902T3 (de)
ES (2) ES2250283T3 (de)
HK (1) HK1020260A1 (de)
HU (2) HU225415B1 (de)
IL (2) IL128059A (de)
NO (2) NO322314B1 (de)
NZ (1) NZ333723A (de)
PT (1) PT930076E (de)
RU (2) RU2220723C2 (de)
WO (1) WO1998002183A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
JP2003518493A (ja) * 1999-12-24 2003-06-10 スミスクライン ビーチャム パブリック リミテッド カンパニー 新規治療方法
EP1326604A2 (de) * 2000-04-12 2003-07-16 Novartis AG Kombination von mindestens 2 aus einer at1-rezeptoren-antagonist- oder einer ace-inhibitor- oder einer hmg-co-a reduktase inhibitorgruppe selektierte wirkstoffe
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
EP1413315A4 (de) * 2001-08-03 2006-08-16 Takeda Pharmaceutical Medikamente mit verzögerter freisetzung
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EP3045174A1 (de) * 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medikament zur vorbeugung und behandlung von arteriosklerose und bluthochdruck
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
AU2005249794A1 (en) * 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
EP1685841A1 (de) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prophylaxe und Behandlung von thrombolischen Erkrankungen
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE502006009169D1 (en) 2005-10-04 2011-05-05 Bayer Schering Pharma Ag NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
NZ612417A (en) * 2008-11-19 2015-02-27 Merial Inc Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
IS1756B (is) * 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP0603419A4 (de) * 1992-07-13 1994-10-12 Japan Tobacco Inc Neue thiazolidindionverbindungen und ihre verwendung.
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
AU6114794A (en) * 1993-02-24 1994-09-14 Sankyo Company Limited Arteriosclerosis remedy
NO303782B1 (no) * 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
CA2186606A1 (en) * 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU713277B2 (en) 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity

Also Published As

Publication number Publication date
CZ300089B6 (cs) 2009-01-28
NZ333723A (en) 2000-09-29
KR100540618B1 (ko) 2006-01-12
KR20000023757A (ko) 2000-04-25
HU227399B1 (en) 2011-05-30
RU2183128C2 (ru) 2002-06-10
ES2250283T3 (es) 2006-04-16
HU225415B1 (en) 2006-11-28
DK0930076T3 (da) 2005-01-31
NO322314B1 (no) 2006-09-11
CN1476833A (zh) 2004-02-25
NO990166D0 (no) 1999-01-14
NO334217B1 (no) 2014-01-13
EP0930076A4 (de) 2001-10-04
NO20056021L (no) 1999-03-15
NO990166L (no) 1999-03-15
PT930076E (pt) 2005-01-31
EP0930076A1 (de) 1999-07-21
AU714618B2 (en) 2000-01-06
ES2232873T3 (es) 2005-06-01
RU2220723C2 (ru) 2004-01-10
CN1221259C (zh) 2005-10-05
EP1175902B1 (de) 2005-10-19
EP1175902A1 (de) 2002-01-30
DE69734405T2 (de) 2006-08-03
AU3459597A (en) 1998-02-09
ATE283704T1 (de) 2004-12-15
IL145758A (en) 2006-06-11
US20020013308A1 (en) 2002-01-31
DE69734405D1 (de) 2006-03-02
CN1230122A (zh) 1999-09-29
CA2261040A1 (en) 1998-01-22
CN1155409C (zh) 2004-06-30
HUP9903166A2 (hu) 2000-09-28
IL128059A (en) 2003-12-10
DE69731840D1 (de) 2005-01-05
CA2261040C (en) 2009-01-20
DE69731840T2 (de) 2005-08-04
HK1020260A1 (en) 2000-04-07
WO1998002183A1 (en) 1998-01-22
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
EP0930076B1 (de) 2004-12-01
IL128059A0 (en) 1999-11-30
HUP9903166A3 (en) 2003-09-29
US6610682B2 (en) 2003-08-26
HU0600501D0 (en) 2006-08-28
DK1175902T3 (da) 2005-12-19
HUP0600501A3 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
ATE306921T1 (de) Verwendung von cs-866 (olmersartan) zur herstellung eines medikaments für die behandlung von arteriosklerose
DE69227115D1 (de) Verwendung von tocopheryl-phosphat sowie einer ihren derivate, für die herstellung von kosmetische oder pharmazeutische zusammensetzungen
ATE97801T1 (de) Mittel zur oralen verwendung.
SE9604786D0 (sv) New compounds
DE69317537D1 (de) Antiallergische Zusammensetzung zur ophthalmischen oder nasalen Anwendung
ATE502932T1 (de) Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
RU2001126527A (ru) Средство и способ лечения или профилактики артериосклероза
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE69506686D1 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATA232687A (de) Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels
ATE191142T1 (de) Verwendung von phenalkylaminen zur herstellung von cholesterinsenkenden arzneimitteln
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ES2094757T3 (es) Un factor megacariocitopoyetico.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE307587T1 (de) Verwendung von thiaminen zur herstellung eines arzneimittels zur prophylaxe und zur therapie der diabetischen retinopathie und der diabetischen nephropathie
DE69626301D1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
ATE128867T1 (de) Verwendung von 3-aryl-5-alkylthio-4h-1,2,4- triazolen zur behandlung von überreflexen infolge von rückenmarkstrauma.
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69516602D1 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175902

Country of ref document: EP